Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.

  • Eva Klopocki
  • Glen Kristiansen
  • Peter J Wild
  • Irina Klaman
  • Esmeralda Castanos-Velez
  • Gad Singer
  • Robert Stöhr
  • Ronald Simon
  • Guido Sauter
  • Haike Leibiger
  • Lutz Essers
  • Birgit Weber
  • Klaus Hermann
  • André Rosenthal
  • Arndt Hartmann
  • Edgar Dahl

Related Research units

Abstract

Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p

Bibliographical data

Original languageGerman
Article number3
ISSN1019-6439
Publication statusPublished - 2004
pubmed 15289865